Healing Study of Fractional Skin Resurfacing and Tissue Histopathology After Ellacor Treatment

NCT ID: NCT06502470

Last Updated: 2024-07-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-30
• Study Completion Date: 2024-05-17

Brief Summary

The goal of this study is to observe the healing of skin after ellacor® treatment at different timepoints, depths and coring densities. The visual comparison of treated areas to untreated control areas will improve understanding of how the ellacor® procedure works to induce skin resurfacing using an abdominoplasty, or tummy tuck surgery, model. The people participating in the study will have already decided that they want to have an abdominoplasty procedure.

The main questions this study aims to answer are:

How does human skin change after a series of the ellacor® procedures over a 14-day period?

Is the ellacor® device safe to use at different treatment time points, depths and densities?

The ellacor® procedure will be performed on people who are going to have abdominoplasty surgery. The ellacor® treatment areas will be limited to the skin areas marked for removal during the abdominoplasty. The treated tissue will be sent to a lab for microscopic study after the abdominoplasty procedure is complete. A minimum of 3 people will be treated in the study.

The 3 participants will have the ellacor® procedure done at 4 different timepoints before their abdominoplasty surgery: -14 days, -7 days, -3 days and on day 0, just prior to the abdominoplasty procedure. At each treatment timepoint the participants will have 3 areas treated using a depth of 7mm and different skin removal percent settings of 5%, 7% and 8%. The participants will have photos taken of the treatment areas and will be asked about any changes to their health or medications over the 14-day study.

Researchers will study the abdominoplasty tissue under a microscope after it has been removed from the participants. They will compare the areas treated by the ellacor® device to an area left untreated, which is the control area. This will reveal, by visual comparison, any changes in the skin tissue between treated and untreated areas, if they occur.

Conditions

Wrinkle; Rhytides; Histopathology

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Safety Evaluation of Skin Removal Percentages and Evaluation of Healing over 14 Days.

Three participants will have the ellacor® procedure done at 4 different timepoints before their abdominoplasty surgery: -14 days, -7 days, -3 days and on day 0, just prior to the abdominoplasty procedure. At each treatment timepoint the participants will have 3 areas treated using different skin removal percent settings: 5%, 7% and 8%. The participants will have photos taken of the treatment areas and will be asked about any changes to their health or medications over the 14-day study.

Group Type: EXPERIMENTAL

ellacor® Micro-Coring procedure

Intervention Type: DEVICE

ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.

Interventions

ellacor® Micro-Coring procedure

ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Undergoing planned abdominoplasty
• Are willing to donate their tissue for evaluation
• BMI ≤ 30
• Women 18 years or older
• Fitzpatrick scale I-VI
• Females of childbearing potential will have a negative urine pregnancy test prior to each procedure
• Are judged to be in good health based on the results of a medical history and physical examination (standard of care for abdominoplasty) at screening
• Has been informed of the nature of the study and agrees to its provisions and has provided written informed consent on a form, as approved by the IRB of the respective clinical site.
• Able and willing to comply with all visits, procedures and evaluation schedules and requirements

Exclusion Criteria

• Having an active bleeding disorder or currently taking anticoagulants
• History of keloid formation or abnormal wound healing
• Inflammation or active infection and treatment area
• Compromised immune system (e.g., diabetes)
• Any surgery or treatments in the abdominal area 12 months prior to procedure
• Comorbid condition that could limit ability to participate in the study or to comply with follow up requirements
• Pregnant or breastfeeding
• Tattoo and/or mole located within the planned treatment area(s)
• Vulnerable populations include those defined 45 CFR 46 Subparts B, and those mentioned in 45 CFR 46.111(b): mentally disabled persons, or economically or educationally disadvantaged persons
• Any issue that at the discretion of the investigator would contraindicate the subject's participation

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Dallas Plastic Surgery Institute

OTHER

Sponsor Role: collaborator

Cytrellis Biosystems, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jill Edgecombe

Role: STUDY_DIRECTOR

Cytrellis Biosystems, Inc.

Locations

Dallas Plastic Surgery Institute

Dallas, Texas, United States

Countries

United States

Other Identifiers

TP-00437

Identifier Type: -

Identifier Source: org_study_id